Items tagged with Pharma industry

South African pharma firms accused of planning to delay patents law reform (post)

Drug companies in South Africa have been accused of planning a covert, well-funded campaign to delay the introduction of laws that threaten their profits. Leaked documents show that pharmaceutical companies planned a $450,000 campaign, involving a high-profile consultancy based in Washington, DC, against changes to intellectual property laws that would enable their patents on new medicines to be bypassed in the interests of public health. This would allow the manufacture of cheaper copies of their medicines.

Janssen announces new group targeting unmet global health needs (post)

Janssen Global Public Health to oversee R&D and access strategy development for growing portfolio of transformational medicines

MSF: AstraZeneca pullout of neglected disease R&D proof system broken (post)

Following news reports that British pharmaceutical producer AstraZeneca will end its spending on early stage research and development for tuberculosis, malaria and neglected tropical diseases, Médecins Sans Frontières issued a statement saying the move is further proof that substantive change to the global pharmaceutical R&D system is needed.

AstraZeneca vs. NTDs: Does profitability win out? (post)

On January 31, 2014, a report was released that AstraZeneca Group plc ADR (AZN) (hereafter, "AZ") announced that it was closing its Avishkar Research & Development facility in Bangalore, India. The closing, which will affect 168 employees, is part of an effort by the British pharmaceutical firm to refocus its resources in R&D. The closing is to take place later this year.1

MSF Director: 'We are losing the battle' for cheap drugs in developing world (post)

José Antonio Bastos, head of doctors without borders (MSF) in Spain, has spoken out against big pharmaceutical companies that "only think in terms of profit" and pay little attention to "real health needs" of the population in developing countries, EurActiv Spain reports.

Big Pharma pushes for U.S. action against India over patent worries (post)

Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.

Battles over patents: Is India changing the rules of the game? (post)

Over the last couple of years, news of pharmaceutical patents and India’s attempts to protect and manage its market has caught the attention of intellectual property observers everywhere and the pharmaceutical industry in particular.

Creating a new ecosystem for drug discovery (post)

This industry needs to forget about intellectual property and pool resources if it is to have any real hope of discovering innovative new medicines, a leading scientist claims.

Global tuberculosis R&D takes hit with AstraZeneca site closure (post)

Last month AstraZeneca said it is shuttering an Indian research site as it moves away from neglected diseases to focus on areas with more potential for growth. With the site shutdown, the company plans to pull out of early-stage research on tropical diseases, tuberculosis and malaria but spare AZD5847, a TB treatment currently in Phase II development.

University defends pharma-funded report from MSF critics (post)

A leading UK university has reacted with bemusement to criticism from Medecins Sans Frontieres about a report it has published regarding the financing of future research at a time when innovative drugmakers are struggling to get what they perceive are fair prices for their therapies.

Page 1 of 7 · Total posts: 0

1 2 Last→